Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents

ACS Medicinal Chemistry Letters

Volumn 6, Issue 7, 2015, Pages 814-818

  Tang, Jian ^a,c   Wang, Bangxing ^a,b   Wu, Tian ^a   Wan, Junting ^a   Tu, Zhengchao ^a   Njire, Moses ^a,c   Wan, Baojie ^d   Franzblauc, Scott G ^d   Zhang, Tianyu ^a   Lu, Xiaoyun ^a   Ding, Ke ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b ANHUI UNIVERSITY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antitubercular agent; H37Rv; pyrazolo 1,5 a pyridine; structure activity relationship; tuberculosis

Indexed keywords

AMIDE; PYRIDINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTITUBERCULAR ACTIVITY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 84936887451     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00176     Document Type: Article

References (23)

1. World Health Organization. Global Tuberculosis Control WHO Report 2014; WHO/HTM/TB/2014.08; 2014.
2. Zumla, A.; Nahid, P.; Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens Nat. Rev. Drug. Discovery 2013, 12 (5) 388-404
3. Zumla, A. I.; Gillespie, S. H.; Hoelscher, M.; Philips, P. P.; Cole, S. T.; Abubakar, I.; McHugh, T. D.; Schito, M.; Maeurer, M.; Nunn, A. J. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects Lancet Infect. Dis. 2014, 14 (4) 327-340
4. Andries, K.; Verhasselt, P.; Guillemont, J.; Gohlmann, H. W.; Neefs, J. M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 2005, 307 (5707) 223-227
5. Cohen, J. Infectious disease. Approval of novel TB drug celebrated - with restraint Science 2013, 339 (6116) 130
6. Diacon, A. H.; Pym, A.; Grobusch, M. P.; de los Rios, J. M.; Gotuzzo, E.; Vasilyeva, I.; Leimane, V.; Andries, K.; Bakare, N.; De Marez, T.; Haxaire-Theeuwes, M.; Lounis, N.; Meyvisch, P.; De Paepe, E.; van Heeswijk, R. P. G.; Dannemann, B. Multidrug-resistant tuberculosis and culture conversion with bedaquiline N. Engl. J. Med. 2014, 371 (8) 723-732
7. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 2000, 405 (6789) 962-966
8. Singh, R.; Manjunatha, U.; Boshoff, H. I.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E., 3rd PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release Science 2008, 322 (5906) 1392-1395
9. Pethe, K.; Bifani, P.; Jang, J.; Kang, S.; Park, S.; Ahn, S.; Jiricek, J.; Jung, J.; Jeon, H. K.; Cechetto, J.; Christophe, T.; Lee, H.; Kempf, M.; Jackson, M.; Lenaerts, A. J.; Pham, H.; Jones, V.; Seo, M. J.; Kim, Y. M.; Seo, M.; Seo, J. J.; Park, D.; Ko, Y.; Choi, I.; Kim, R.; Kim, S. Y.; Lim, S.; Yim, S.-A.; Nam, J.; Kang, H.; Kwon, H.; Oh, C.-T.; Cho, Y.; Jang, Y.; Kim, J.; Chua, A.; Tan, B. H.; Nanjundappa, M. B.; Rao, S. P. S.; Barnes, W. S.; Wintjens, R.; Walker, J. R.; Alonso, S.; Lee, S.; Kim, J.; Oh, S.; Oh, T.; Nehrbass, U.; Han, S.-J.; No, Z.; Lee, J.; Brodin, P.; Cho, S.-N.; Nam, K.; Kim, J. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis Nat. Med. 2013, 19 (9) 1157-1160
10. Kang, S.; Kim, R. Y.; Seo, M. J.; Lee, S.; Kim, Y. M.; Seo, M.; Seo, J. J.; Ko, Y.; Choi, I.; Jang, J.; Nam, J.; Park, S.; Kang, H.; Kim, H. J.; Kim, J.; Ahn, S.; Pethe, K.; Nam, K.; No, Z.; Kim, J. Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent J. Med. Chem. 2014, 57 (12) 5293-5305
11. Abrahams, K. A.; Cox, J. A. G.; Spivey, V. L.; Loman, N. J.; Pallen, M. J.; Constantinidou, C.; Fernández, R.; Alemparte, C.; Remuiñán, M. J.; Barros, D.; Ballell, L.; Besra, G. S. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB PLoS One 2012, 7 (12) e52951
12. Moraski, G. C.; Markley, L. D.; Hipskind, P. A.; Boshoff, H.; Cho, S.; Franzblau, S. G.; Miller, M. J. Advent of imidazo[1,2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity ACS Med. Chem. Lett. 2011, 2 (6) 466-470
13. Moraski, G. C.; Markley, L. D.; Cramer, J.; Hipskind, P. A.; Boshoff, H.; Bailey, M.; Alling, T.; Ollinger, J.; Parish, T.; Miller, M. J. Advancement of imidazo[1,2-]pyridines with improved pharmacokinetics and nanomolar activity vs Mycobacterium tuberculosis ACS Med. Chem. Lett. 2013, 4 (7) 675-679
14. Bald, D.; Koul, A. Respiratory ATP synthesis: the new generation of mycobacterial drug targets? FEMS Microbiol. Lett. 2010, 308 (1) 1-7
15. Nishino, K.; Ohkubo, H.; Ohashi, M.; Hara, S.; Kito, J.; Irikura, T. KC-404: a potential anti-allergic agent with antagonistic action against slow reacting substance of anaphylaxis Jpn. J. Pharmacol. 1983, 33 (2) 267-278
16. Awano, K.; Suzue, S.; Segawa, M. Synthesis of 3-substituted pyrazolo[1,5-a]pyridine derivatives with inhibitory activity on platelet aggregation. I Chem. Pharm. Bull. 1986, 34 (7) 2828-2832
17. Lober, S.; Hubner, H.; Utz, W.; Gmeiner, P. Rationally based efficacy tuning of selective dopamine d4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213) J. Med. Chem. 2001, 44 (17) 2691-2694
18. D. Kendall, J. Synthesis and reactions of pyrazolo[1,5-a]pyridines and related heterocycles Curr. Org. Chem. 2011, 15 (14) 2481-2518
19. Yang, F.; Njire, M. M.; Liu, J.; Wu, T.; Wang, B.; Liu, T.; Cao, Y.; Liu, Z.; Wan, J.; Tu, Z.; Tan, Y.; Tan, S.; Zhang, T. Engineering more stable, selectable marker-free autoluminescent mycobacteria by one step PLoS One 2015, 10 (3) e0119341
20. Zhang, T.; Li, S. Y.; Nuermberger, E. L. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy PLoS One 2012, 7 (1) e29774
21. Collins, L.; Franzblau, S. G. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Chemother. 1997, 41 (5) 1004-1009
22. Ollinger, J.; Bailey, M. A.; Moraski, G. C.; Casey, A.; Florio, S.; Alling, T.; Miller, M. J.; Parish, T. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis PLoS One 2013, 8 (4) e60531
23. Tan, Y.; Hu, Z.; Zhang, T.; Cai, X.; Kuang, H.; Liu, Y.; Chen, J.; Yang, F.; Zhang, K.; Tan, S.; Zhao, Y. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China J. Clin. Microbiol. 2014, 52 (1) 291-297